The Readout LOUD

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come. Subscribe today on iTunes, Spotify, SoundCloud, and Stitcher.

All Coverage

The Readout LOUD Meg Tirrell, Adam Feuerstein and Damian Garde

STAT Plus: Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and much more

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Vas Narasimhan on the future of pharma, plus Moderna’s vaccine promise & a biotech presidential bid

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

The ‘electric vehicles’ of pharma, Illumina’s boondoggle, & a Theranos sentencing

The Readout LOUD Adam Feuerstein, Damian Garde and Allison DeAngelis

Listen: Whither PhRMA, Alzheimer’s treatment data revealed, and the first fecal microbiome drug approval

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

BU’s Covid tinkering, FDA on trial, & why it’s hard to take drugs off the market

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

BIO’s messy transition, mRNA’s future, & Biogen’s next CEO

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Nobels for science, biotech dealmaking, & a friendly FTC

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Pharma’s telehealth gold mine, the return of the biotech IPO, & a merger deferred

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

The Readout LOUD Damian Garde and Allison DeAngelis

Fauci’s non-retirement, grading biotech VCs, & a bellwether IPO

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Private equity in autism care, a watershed FDA approval, and the future of ALS treatment

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: The last-minute push for drug pricing reform, Alnylam’s success, and Sarepta’s gamble

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer’s data

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Well-paid CEOs, behind the scenes at Moderna, & Biogen’s CEO search

The Readout LOUD Damian Garde and Adam Feuerstein

Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’

The Readout LOUD Damian Garde and Adam Feuerstein

Listen: VC malaise, FDA confusion, & yet another Alzheimer’s debate

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

The Readout LOUD

Most Read

Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection

Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score

#JPM23 in review, the year ahead, & the merits of Miami

Listen: #JPM23, the future of Alzheimer’s, & rising Covid variants

2022 in review, CEO indictments, & the year ahead

Listen: Roche’s failure, Eisai’s success, and a live AMA

Listen: Biogen’s new CEO, how the midterms affect science, & a biotech bankruptcy

Listen: How the biotech revolution could come apart at the seams

All Coverage

STAT Plus: Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and much more

Listen: Vas Narasimhan on the future of pharma, plus Moderna’s vaccine promise & a biotech presidential bid

Listen: The return of bird flu and the effects of pandemic fatigue

Listen: Pharma blockbusters, pandemic policy, & legal chicanery

Listen: Leaky health data, ASH22, & what it takes to get booed by your peers

The ‘electric vehicles’ of pharma, Illumina’s boondoggle, & a Theranos sentencing

Listen: Whither PhRMA, Alzheimer’s treatment data revealed, and the first fecal microbiome drug approval

Listen: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

BU’s Covid tinkering, FDA on trial, & why it’s hard to take drugs off the market

BIO’s messy transition, mRNA’s future, & Biogen’s next CEO

Listen: Nobels for science, biotech dealmaking, & a friendly FTC

Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy

Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0

Listen: Pharma’s telehealth gold mine, the return of the biotech IPO, & a merger deferred

Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

Listen: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

Fauci’s non-retirement, grading biotech VCs, & a bellwether IPO

Listen: Private equity in autism care, a watershed FDA approval, and the future of ALS treatment

Listen: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing

Listen: The last-minute push for drug pricing reform, Alnylam’s success, and Sarepta’s gamble

Listen: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer’s data

Listen: Well-paid CEOs, behind the scenes at Moderna, & Biogen’s CEO search

Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’

Listen: VC malaise, FDA confusion, & yet another Alzheimer’s debate

Listen: Medical privacy post-Roe, fixing clinical trials, & the next Covid vaccines

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day

Subscribe to STAT+ for less than $2 per day